ST. LOUIS, February 03, 2022 – Industry veteran Christine Versichele, B.S.N., M.S.P., has recently joined ANiGENT, a fast-growing Midwest drug diversion solution provider, as a brand ambassador. The role will leverage Versichele’s experience as a former intensive care unit nurse and national account manager to promote the company’s initiatives and help establish ANiGENT as a trusted drug diversion prevention company. In addition, she will use her expertise in changing healthcare trends to develop effective strategies and find configurable solutions for hospitals’ needs.
“We are excited to bring Christine Versichele into the ANiGENT team,” said ANiGENT CEO Virgilio “Jun” Fabella, Jr. “The reputation she has developed as a trusted voice within the healthcare space will only help ANiGENT amplify its voice as the premier drug diversion prevention solution.”
Versichele joins ANiGENT after working for analytical testing laboratory DYNALABS, where she focused on developing relationships with clients at health systems and state boards of pharmacy. She utilized her industry expertise to support the company’s sales teams in crafting successful business strategies. Her focus enabled DYNALABS to facilitate the tracking of drug diversion for hospitals in the western United States.
“Christine’s experience on the clinical floor is invaluable,” said Fabella, Jr. “Experiencing the day-to-day activities of a hospital means understanding what is actively required to safeguard patient safety on the floor.”
Versichele holds a Bachelor of Science in Nursing from Nazareth College and a Master of Science in Pharmacy from the University of Florida. For six years, she served as a nurse in critical care and intensive care units at Bronson Hospital in Kalamazoo, Mich.; Providence Hospital in Southfield, Mich.; and Bon Secours Hospital in Grosse Pointe, Mich., before transitioning to a strategic role as the U.S. director of channel strategies for Pfizer’s Greenstone division in 2001 and as a regional account manager at DYNALABS in 2014.
###
About ANiGENT
ANiGENT was established in 2019 to deliver a comprehensive, patent-pending drug diversion detection platform: Medication Administration & Analysis Program (MAAP Analytics). Built by clinicians for clinicians, MAAP Analytics® uses machine learning to track all users, all medications, in all locations and identify the root cause of discrepancies in minutes. Purpose-built and proven to produce actionable intelligence, MAAP Analytics is operationally efficient and configurable to any facility’s requirements. To learn more about ANiGENT and MAAP Analytics, visit https://ANiGENT.com/
ANiGENT was established in 2019 to deliver a comprehensive, patent-pending drug diversion detection platform: Medication Administration & Analysis Program (MAAP Analytics®). Built by clinicians for clinicians and backed by over 10 years of refinements in a clinical setting, MAAP Analytics uses machine learning to track all users, all medications, in all locations and identify the root cause of discrepancies in minutes. Purpose-built and proven to produce actionable intelligence, MAAP Analytics is operationally efficient and configurable to any facility’s requirements. To learn more about ANiGENT and MAAP Analytics, visit ANiGENT.com.
This post is related to:
Drug Diversion Monitoring, Diversion Prevention
